<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02742532</url>
  </required_header>
  <id_info>
    <org_study_id>NMCSD Oxytocin</org_study_id>
    <nct_id>NCT02742532</nct_id>
  </id_info>
  <brief_title>Oxytocin Suppresses Substance Use Disorders Associated With Chronic Stress</brief_title>
  <official_title>Oxytocin Suppresses Substance Use Disorders Associated With Chronic Stress</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Jennifer Mitchell</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>United States Naval Medical Center, San Diego</agency>
      <agency_class>U.S. Fed</agency_class>
    </collaborator>
    <collaborator>
      <agency>United States Department of Defense</agency>
      <agency_class>U.S. Fed</agency_class>
    </collaborator>
    <collaborator>
      <agency>Congressionally Directed Medical Research Programs</agency>
      <agency_class>U.S. Fed</agency_class>
    </collaborator>
    <collaborator>
      <agency>Eisenhower Army Medical Center</agency>
      <agency_class>U.S. Fed</agency_class>
    </collaborator>
  </sponsors>
  <source>University of California, San Francisco</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>Yes</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of this study is to determine whether oxytocin will decrease craving to use&#xD;
      drugs/alcohol and stress reactivity following exposure to laboratory-induced stress among&#xD;
      Active Duty Service Members with a dual diagnosis of alcohol/substance use disorder (ASUD)&#xD;
      and post-traumatic anxiety.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      The purpose of this study is to determine whether intra-nasally administered oxytocin will&#xD;
      decrease craving to use alcohol and stress reactivity following exposure to&#xD;
      laboratory-induced stress among Active Duty Service Members (AD SMs) with a dual diagnosis of&#xD;
      alcohol/substance use disorder (ASUD) and post-traumatic anxiety (i.e., PTSD or anxiety&#xD;
      disorder NOS).&#xD;
&#xD;
      This is a 2-arm placebo controlled study. Subjects will complete a battery of self-report&#xD;
      questionnaires and behavioral interviews. Baseline assessments of subjective (craving,&#xD;
      stress), physiologic (HR, BP), and neuroendocrine measures (salivary cortisol) will be&#xD;
      collected. These same assessments will be repeatedly collected throughout the testing portion&#xD;
      of the study. Subjects will receive acute administration of intra-nasal oxytocin or placebo&#xD;
      and will then be exposed to a laboratory-induced social stressor. They will be asked to give&#xD;
      a short speech and perform arithmetic in front of a panel of judges. Following the task,&#xD;
      additional post-task assessments of the subjective, physiological, and neuroendocrine&#xD;
      measures will be completed over the next hour.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date type="Actual">April 20, 2017</start_date>
  <completion_date type="Actual">July 1, 2019</completion_date>
  <primary_completion_date type="Actual">July 1, 2019</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Basic Science</primary_purpose>
    <masking>Triple (Participant, Care Provider, Investigator)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Change in Craving to Use Alcohol Rating (Visual Analog Scale)</measure>
    <time_frame>Change from baseline to post-drug at 20 minutes</time_frame>
    <description>The Visual Analog Scale (VAS) is a horizontal line of fixed 100 mm length. The ends are defined as the extreme limits of the parameter from the left (least) to the right (most). Subjects mark the point on the line that represents their perception of the parameter. The score is determined by measuring in millimeters from the left end of the line to the point that the patient marks. The score range is 0-100, with higher scores indicating higher cravings.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Change in Stress Rating (Visual Analog Scale)</measure>
    <time_frame>Change from baseline to post-drug at 20 minutes</time_frame>
    <description>The Visual Analog Scale (VAS) is a horizontal line of fixed 100 mm length. The ends are defined as the extreme limits of the parameter from the left (least) to the right (most). Subjects mark the point on the line that represents their perception of the parameter. The score is determined by measuring in millimeters from the left end of the line to the point that the patient marks. The score range is 0-100, with higher scores indicating higher stress.</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">63</enrollment>
  <condition>Alcohol Use Disorder</condition>
  <condition>Stress Disorders, Post-Traumatic</condition>
  <condition>Anxiety Disorders</condition>
  <condition>Substance Use Disorders</condition>
  <arm_group>
    <arm_group_label>Oxytocin</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Intra-nasal oxytocin (40 IUs; 5 puffs in each nostril)</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Placebo</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Intra-nasal saline placebo (5 puffs in each nostril)</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Oxytocin</intervention_name>
    <description>Intranasal oxytocin 40 IU</description>
    <arm_group_label>Oxytocin</arm_group_label>
    <other_name>Syntocinon nasal spray</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Placebo</intervention_name>
    <description>Intranasal saline solution</description>
    <arm_group_label>Placebo</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Active Duty Service Members, any service branch; age 18-65 years.&#xD;
&#xD;
          -  Meets clinician assessment for current PTSD OR anxiety disorder NOS OR scores on DASS&#xD;
             &gt; 10 on Anxiety or &gt; 19 on Stress.&#xD;
&#xD;
          -  Meets clinician assessment for alcohol use disorder (AUD) OR scores &gt;8 on AUDIT.&#xD;
&#xD;
          -  If meet current or lifetime criteria for another substance disorder, must indicate&#xD;
             that AUD is primary.&#xD;
&#xD;
          -  Subjects taking psychotropic medications will be required to be maintained on a stable&#xD;
             dose for at least two weeks before study initiation (unless at physician's discretion&#xD;
             following psychological consult).&#xD;
&#xD;
          -  Negative urine drug screen test and BAC =0.&#xD;
&#xD;
          -  Able to comprehend English.&#xD;
&#xD;
          -  Able to provide informed consent and function at an intellectual level sufficient to&#xD;
             allow completion of the assessment instruments.&#xD;
&#xD;
          -  Must consent to random assignment to oxytocin or placebo.&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Positive urine drug screen (except marijuana) or BAC &gt; 0.&#xD;
&#xD;
          -  Untreated subjects currently symptomatic of psychotic or bipolar affective disorders.&#xD;
&#xD;
          -  Subjects with current suicidal or homicidal ideation and intent, who would present a&#xD;
             serious suicide risk.&#xD;
&#xD;
          -  Subjects on psychotropic drugs that have been initiated during the past 2 weeks&#xD;
             (unless approved at physician's discretion following psychological consult).&#xD;
&#xD;
          -  Subjects with a history of a major medical illness (e.g., endocrine, cardiovascular,&#xD;
             central nervous system disorders, peripheral neuropathy, or pulmonary disease) or&#xD;
             other acute or unstable medical condition that might interfere with safe conduct of&#xD;
             the study or accurate interpretation of the results.&#xD;
&#xD;
          -  Subjects experiencing withdrawal symptoms as reported by Clinician or systolic BP≥160&#xD;
             mmHg, diastolic BP ≥100 mmHg and resting HR ≥100 bpm.&#xD;
&#xD;
          -  Subject is considered unsuitable for the study in the opinion of study PI or AIs for&#xD;
             any other reason.&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>65 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Mardi Smith, PhD</last_name>
    <role>Principal Investigator</role>
    <affiliation>United States Naval Medical Center, San Diego</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Naval Medical Center San Diego</name>
      <address>
        <city>San Diego</city>
        <state>California</state>
        <zip>92106</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>September 2020</verification_date>
  <study_first_submitted>April 14, 2016</study_first_submitted>
  <study_first_submitted_qc>April 14, 2016</study_first_submitted_qc>
  <study_first_posted type="Estimate">April 19, 2016</study_first_posted>
  <results_first_submitted>August 19, 2020</results_first_submitted>
  <results_first_submitted_qc>September 21, 2020</results_first_submitted_qc>
  <results_first_posted type="Actual">October 19, 2020</results_first_posted>
  <last_update_submitted>September 21, 2020</last_update_submitted>
  <last_update_submitted_qc>September 21, 2020</last_update_submitted_qc>
  <last_update_posted type="Actual">October 19, 2020</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor-Investigator</responsible_party_type>
    <investigator_affiliation>University of California, San Francisco</investigator_affiliation>
    <investigator_full_name>Jennifer Mitchell</investigator_full_name>
    <investigator_title>Associate Professor</investigator_title>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Disease</mesh_term>
    <mesh_term>Substance-Related Disorders</mesh_term>
    <mesh_term>Alcoholism</mesh_term>
    <mesh_term>Anxiety Disorders</mesh_term>
    <mesh_term>Stress Disorders, Post-Traumatic</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Oxytocin</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <provided_document_section>
    <provided_document>
      <document_type>Study Protocol and Statistical Analysis Plan</document_type>
      <document_has_protocol>Yes</document_has_protocol>
      <document_has_icf>No</document_has_icf>
      <document_has_sap>Yes</document_has_sap>
      <document_date>June 5, 2019</document_date>
      <document_url>https://ClinicalTrials.gov/ProvidedDocs/32/NCT02742532/Prot_SAP_001.pdf</document_url>
    </provided_document>
  </provided_document_section>

  <clinical_results>

    <participant_flow>
      <group_list>
        <group group_id="P1">
          <title>Oxytocin</title>
          <description>Intra-nasal oxytocin (40 IUs; 5 puffs in each nostril)&#xD;
Oxytocin: Intranasal oxytocin 40 IU</description>
        </group>
        <group group_id="P2">
          <title>Placebo</title>
          <description>Intra-nasal saline placebo (5 puffs in each nostril)&#xD;
Placebo: Intranasal saline solution</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Overall Study</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="31"/>
                <participants group_id="P2" count="32"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="28"/>
                <participants group_id="P2" count="31"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="3"/>
                <participants group_id="P2" count="1"/>
              </participants_list>
            </milestone>
          </milestone_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <group_list>
        <group group_id="B1">
          <title>Oxytocin</title>
          <description>Intra-nasal oxytocin (40 IUs; 5 puffs in each nostril)&#xD;
Oxytocin: Intranasal oxytocin 40 IU</description>
        </group>
        <group group_id="B2">
          <title>Placebo</title>
          <description>Intra-nasal saline placebo (5 puffs in each nostril)&#xD;
Placebo: Intranasal saline solution</description>
        </group>
        <group group_id="B3">
          <title>Total</title>
          <description>Total of all reporting groups</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="31"/>
            <count group_id="B2" value="32"/>
            <count group_id="B3" value="63"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="B1" value="31"/>
                    <count group_id="B2" value="32"/>
                    <count group_id="B3" value="63"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <title>&lt;=18 years</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Between 18 and 65 years</title>
                  <measurement_list>
                    <measurement group_id="B1" value="31"/>
                    <measurement group_id="B2" value="32"/>
                    <measurement group_id="B3" value="63"/>
                  </measurement_list>
                </category>
                <category>
                  <title>&gt;=65 years</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Age</title>
          <units>years</units>
          <param>Mean</param>
          <dispersion>Full Range</dispersion>
          <class_list>
            <class>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="B1" value="31"/>
                    <count group_id="B2" value="32"/>
                    <count group_id="B3" value="63"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="27.09" lower_limit="19" upper_limit="45"/>
                    <measurement group_id="B2" value="27.38" lower_limit="20" upper_limit="42"/>
                    <measurement group_id="B3" value="27.24" lower_limit="19" upper_limit="45"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Sex: Female, Male</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="B1" value="31"/>
                    <count group_id="B2" value="32"/>
                    <count group_id="B3" value="63"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <title>Female</title>
                  <measurement_list>
                    <measurement group_id="B1" value="5"/>
                    <measurement group_id="B2" value="3"/>
                    <measurement group_id="B3" value="8"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Male</title>
                  <measurement_list>
                    <measurement group_id="B1" value="26"/>
                    <measurement group_id="B2" value="29"/>
                    <measurement group_id="B3" value="55"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Race (NIH/OMB)</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="B1" value="31"/>
                    <count group_id="B2" value="32"/>
                    <count group_id="B3" value="63"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <title>American Indian or Alaska Native</title>
                  <measurement_list>
                    <measurement group_id="B1" value="1"/>
                    <measurement group_id="B2" value="1"/>
                    <measurement group_id="B3" value="2"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Asian</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="1"/>
                    <measurement group_id="B3" value="1"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Native Hawaiian or Other Pacific Islander</title>
                  <measurement_list>
                    <measurement group_id="B1" value="2"/>
                    <measurement group_id="B2" value="1"/>
                    <measurement group_id="B3" value="3"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Black or African American</title>
                  <measurement_list>
                    <measurement group_id="B1" value="2"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="2"/>
                  </measurement_list>
                </category>
                <category>
                  <title>White</title>
                  <measurement_list>
                    <measurement group_id="B1" value="25"/>
                    <measurement group_id="B2" value="29"/>
                    <measurement group_id="B3" value="54"/>
                  </measurement_list>
                </category>
                <category>
                  <title>More than one race</title>
                  <measurement_list>
                    <measurement group_id="B1" value="1"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="1"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Unknown or Not Reported</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Region of Enrollment</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>United States</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="B1" value="31"/>
                    <count group_id="B2" value="32"/>
                    <count group_id="B3" value="63"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="31"/>
                    <measurement group_id="B2" value="32"/>
                    <measurement group_id="B3" value="63"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Self-Reported Alcoholic drinks per week</title>
          <population>Some subjects declined to complete this data, so the row population differs from the overall.</population>
          <units>standard drinks/week</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="B1" value="28"/>
                    <count group_id="B2" value="30"/>
                    <count group_id="B3" value="58"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="51.2" spread="39.9"/>
                    <measurement group_id="B2" value="43.9" spread="45.9"/>
                    <measurement group_id="B3" value="47.4" spread="42.9"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>Change in Craving to Use Alcohol Rating (Visual Analog Scale)</title>
        <description>The Visual Analog Scale (VAS) is a horizontal line of fixed 100 mm length. The ends are defined as the extreme limits of the parameter from the left (least) to the right (most). Subjects mark the point on the line that represents their perception of the parameter. The score is determined by measuring in millimeters from the left end of the line to the point that the patient marks. The score range is 0-100, with higher scores indicating higher cravings.</description>
        <time_frame>Change from baseline to post-drug at 20 minutes</time_frame>
        <population>All subjects who completed this outcome measure were included.</population>
        <group_list>
          <group group_id="O1">
            <title>Oxytocin</title>
            <description>Intra-nasal oxytocin (40 IUs; 5 puffs in each nostril)&#xD;
Oxytocin: Intranasal oxytocin 40 IU</description>
          </group>
          <group group_id="O2">
            <title>Placebo</title>
            <description>Intra-nasal saline placebo (5 puffs in each nostril)&#xD;
Placebo: Intranasal saline solution</description>
          </group>
        </group_list>
        <measure>
          <title>Change in Craving to Use Alcohol Rating (Visual Analog Scale)</title>
          <description>The Visual Analog Scale (VAS) is a horizontal line of fixed 100 mm length. The ends are defined as the extreme limits of the parameter from the left (least) to the right (most). Subjects mark the point on the line that represents their perception of the parameter. The score is determined by measuring in millimeters from the left end of the line to the point that the patient marks. The score range is 0-100, with higher scores indicating higher cravings.</description>
          <population>All subjects who completed this outcome measure were included.</population>
          <units>score on a scale</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="29"/>
                <count group_id="O2" value="32"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.076" spread="1.77"/>
                    <measurement group_id="O2" value="-0.928" spread="1.42"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Change in Stress Rating (Visual Analog Scale)</title>
        <description>The Visual Analog Scale (VAS) is a horizontal line of fixed 100 mm length. The ends are defined as the extreme limits of the parameter from the left (least) to the right (most). Subjects mark the point on the line that represents their perception of the parameter. The score is determined by measuring in millimeters from the left end of the line to the point that the patient marks. The score range is 0-100, with higher scores indicating higher stress.</description>
        <time_frame>Change from baseline to post-drug at 20 minutes</time_frame>
        <population>All subjects who completed this outcome measure were included.</population>
        <group_list>
          <group group_id="O1">
            <title>Oxytocin</title>
            <description>Intra-nasal oxytocin (40 IUs; 5 puffs in each nostril)&#xD;
Oxytocin: Intranasal oxytocin 40 IU</description>
          </group>
          <group group_id="O2">
            <title>Placebo</title>
            <description>Intra-nasal saline placebo (5 puffs in each nostril)&#xD;
Placebo: Intranasal saline solution</description>
          </group>
        </group_list>
        <measure>
          <title>Change in Stress Rating (Visual Analog Scale)</title>
          <description>The Visual Analog Scale (VAS) is a horizontal line of fixed 100 mm length. The ends are defined as the extreme limits of the parameter from the left (least) to the right (most). Subjects mark the point on the line that represents their perception of the parameter. The score is determined by measuring in millimeters from the left end of the line to the point that the patient marks. The score range is 0-100, with higher scores indicating higher stress.</description>
          <population>All subjects who completed this outcome measure were included.</population>
          <units>score on a scale</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="29"/>
                <count group_id="O2" value="32"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-0.755" spread="1.24"/>
                    <measurement group_id="O2" value="-1.268" spread="1.82"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
    </outcome_list>

    <reported_events>
      <time_frame>From enrollment through study completion, an average of 1 year</time_frame>
      <group_list>
        <group group_id="E1">
          <title>Oxytocin</title>
          <description>Intra-nasal oxytocin (40 IUs; 5 puffs in each nostril)&#xD;
Oxytocin: Intranasal oxytocin 40 IU</description>
        </group>
        <group group_id="E2">
          <title>Placebo</title>
          <description>Intra-nasal saline placebo (5 puffs in each nostril)&#xD;
Placebo: Intranasal saline solution</description>
        </group>
      </group_list>
      <serious_events>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, all-cause mortality</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="31"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="32"/>
              </event>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="31"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="32"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>5</frequency_threshold>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="31"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="32"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>All Principal Investigators ARE employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>There is NOT an agreement between Principal Investigators and the Sponsor (or its agents) that restricts the PI's rights to discuss or publish trial results after the trial is completed. </restrictive_agreement>
    </certain_agreements>
    <point_of_contact>
      <name_or_title>Jennifer Mitchell, PhD</name_or_title>
      <organization>University of California, San Francisco</organization>
      <phone>510-985-3921</phone>
      <email>jennifer.mitchell@ucsf.edu</email>
    </point_of_contact>
  </clinical_results>
</clinical_study>

